60 Degrees Pharmaceuticals Inc. (SXTP)
NASDAQ: SXTPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SXTP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.10M
- EPS (TTM)
- -$5.34
- Dividend yield
- None
- 52-week range
- 0.46 – 8.62
- Day range
- 0.46 – 0.4998
- Volume / Avg
- 51.29K / 407.29K
- Beta
- —
- Shares outstanding
- 4.48M
52-week range
SXTP stock today
Shares of 60 Degrees Pharmaceuticals (SXTP) finished lower on Nov 20 at $0.4682, a drop of 6.36% or $0.0318 per share, versus the S&P 500's 3.70% decline. Trading was light, with 51.29K shares changing hands, about 13% of the average daily volume. Shares are 94.6% below their 52-week high of $8.62 and 1.8% above the 52-week low of $0.46, near the bottom of the past year's range.
60 Degrees Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About 60 Degrees Pharmaceuticals
Company profile60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Geoffrey Stuart Dow Ph.D.
- Headquarters
- Washington, DC
- Employees
- 3
- IPO year
- 2023
- Website
- 60degreespharma.com
Financial highlights
Full financialsIn fiscal 2025, 60 Degrees Pharmaceuticals generated $1.0 million in revenue, up 65.5% from fiscal 2024, its 3rd consecutive year of revenue growth. 60 Degrees Pharmaceuticals reported a net loss of $7.4 million, compared with a loss of $7.9 million a year earlier. Gross margin was 22.3% (down from 36.7%) and operating margin -771.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $1.01M | $607.57K | $253.57K | $223.21K |
| Growth | +65.49% | +139.61% | +13.60% | — |
| Net income | $-7.37M | $-7.95M | $-3.77M | $-6.18M |
| EPS (diluted) | $-11.73 | $-74.17 | $-59.18 | $-2.61 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$3.70+690.26%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.75 vs $-0.73
- Surprise
- -2.74%
SXTP news
All SXTP news- 60 Degrees Pharmaceuticals, Inc. Received Nasdaq Notice Regarding Minimum Bid Price and Delisting DeterminationNasdaq
- 60 Degrees Pharma Expands Research Into Alpha-Gal Syndrome; Stock UpNasdaqSXTP, BRK.B
- 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal SyndromeGlobeNewswire
- 60 Degrees Pharmaceuticals, Inc. Reports Results from Expanded Access Babesiosis StudyNasdaq
- 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study PatientsGlobeNewswire
- 60 Degrees Pharmaceuticals, Inc. Outlines Tafenoquine Clinical Program for Babesiosis and Potential sNDA in 2027Nasdaq
60 Degrees Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KAPAKairos Pharma Ltd. | 0.4359 | -4.62% | $2.04M | vs SXTP |
| ENLVEnlivex Ltd. | 1.05 | -11.76% | $2.01M | vs SXTP |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.2449 | +15.03% | $2.19M | vs SXTP |
| REVBRevelation Biosciences Inc. | 3.50 | -5.15% | $1.99M | vs SXTP |
| DCOYDecoy Therapeutics Inc. | 0.8294 | -4.68% | $1.98M | vs SXTP |
| GNPXGenprex Inc. | 1.45 | -13.17% | $1.94M | vs SXTP |
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs SXTP |
| ERNAErnexa Therapeutics Inc. | 1.36 | -16.56% | $2.30M | vs SXTP |
Indexes, lists and sector
60 Degrees Pharmaceuticals stock FAQ
What is 60 Degrees Pharmaceuticals's stock price today?
SXTP last traded at $0.4682 as of Nov 20, 4:00 PM EST, down 6.36% on the day. Prices are delayed at least 15 minutes.
Who is 60 Degrees Pharmaceuticals's CEO?
Dr. Geoffrey Stuart Dow Ph.D. is the chief executive officer of 60 Degrees Pharmaceuticals Inc., which has about 3 employees.
What is the SXTP 52-week high?
The 52-week high for SXTP is $8.62 and the 52-week low is $0.46. The stock is currently 94.6% below its high.